FindTrial
Sign In

Prognostic Model for Resected Borderline and Locally Advanced Pancreatic Cancer after Neoadjuvant Chemotherapy

Prognostic Nomogram Considering Pathology and Biologic Parameters for Resected Borderline Resectable and Locally Advanced Pancreatic Cancer (BRPC & LAPC) Following Neoadjuvant Chemotherapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0009203
Enrollment
176
Registered
2024-02-26
Start date
2022-12-09
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Asan Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Among patients who was treated in Seoul Asan Medical Center, those with available preoperative CA 19-9 level and PET result

Exclusion criteria

Exclusion criteria: No Curative resection, No available preoperativel level of CA 19-9, No available preoperative PET

Design outcomes

Primary

MeasureTime frame
5year Overall survival—

Secondary

MeasureTime frame
Recurrence free survival—

Countries

Korea, Republic of

Contacts

Public ContactJIMIN SON

Asan Medical Center

slam0807@gmail.com+82-2-3010-0047

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026